Provided by Tiger Trade Technology Pte. Ltd.

Kiniksa Pharmaceuticals Ltd.

43.96
+0.68001.57%
Post-market: 43.960.00000.00%16:10 EST
Volume:485.25K
Turnover:21.17M
Market Cap:3.33B
PE:94.17
High:44.16
Open:43.34
Low:43.15
Close:43.28
52wk High:45.00
52wk Low:18.12
Shares:75.80M
Float Shares:35.24M
Volume Ratio:0.74
T/O Rate:1.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.4668
EPS(LYR):-0.6047
ROE:7.39%
ROA:3.76%
PB:6.22
PE(LYR):-72.69

Loading ...

Earnings Flash (KNSA) Kiniksa Pharmaceuticals Posts Q3 EPS $0.23, vs. FactSet Est of $0.32

MT Newswires Live
·
Oct 28, 2025

Kiniksa Pharmaceuticals Q3 2025 EPS $0.23 Misses $0.26 Estimate, Sales $180.855M Beat $167.358M Estimate

Benzinga
·
Oct 28, 2025

BRIEF-Kiniksa Pharmaceuticals Q3 EPS USD 0.25

Reuters
·
Oct 28, 2025

Kiniksa Pharmaceuticals: on-Track for Phase 2 Date Dose-Focusing Portion of the Kpl-387 Phase 2/3 Recurrent Pericarditis Trial in H2 2026

THOMSON REUTERS
·
Oct 28, 2025

Kiniksa Pharmaceuticals Q3 Operating Expenses USD 156.834 Million

THOMSON REUTERS
·
Oct 28, 2025

Kiniksa Pharmaceuticals International Plc Expects 2025 Arcalyst Net Product Revenue of Between $670 Million and $675 Million

THOMSON REUTERS
·
Oct 28, 2025

Kiniksa Pharmaceuticals International Expects Its Current Operating Plan to Remain Cash Flow Positive on an Annual Basis

THOMSON REUTERS
·
Oct 28, 2025

Kiniksa Pharmaceuticals International PLC expected to post earnings of 32 cents a share - Earnings Preview

Reuters
·
Oct 24, 2025

Kiniksa Pharmaceuticals Chairman and CEO Sanj K. Patel Reports Disposal of Common Shares

Reuters
·
Oct 23, 2025

Kiniksa Pharmaceuticals Is Maintained at Buy by Citigroup

Dow Jones
·
Oct 17, 2025

How FDA Orphan Drug Status for KPL-387 at Kiniksa (KNSA) Has Changed Its Investment Story

Simply Wall St.
·
Oct 17, 2025

Kiniksa Pharmaceuticals Gets Orphan Drug Designation for KPL-387

Dow Jones
·
Oct 17, 2025

Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for Kpl-387 for the Treatment of Pericarditis

THOMSON REUTERS
·
Oct 17, 2025

Kiniksa Pharmaceuticals International Plc - Kpl-387 Phase 2/3 Trial Data Expected in Second Half of 2026

THOMSON REUTERS
·
Oct 17, 2025

Kiniksa price target raised to $50 from $45 at Citi

TIPRANKS
·
Oct 17, 2025

Kiniksa Pharmaceuticals International Plc : Citigroup Raises Target Price to $50 From $45

THOMSON REUTERS
·
Oct 17, 2025

Kiniksa granted orphan designation for treatment of pericarditis

TIPRANKS
·
Oct 17, 2025

Kiniksa Pharmaceuticals COO Eben Tessari Reports Disposal of Common Shares

Reuters
·
Oct 17, 2025

Kiniksa Pharmaceuticals Is Maintained at Outperform by Wedbush

Dow Jones
·
Oct 13, 2025

Wedbush Lifts Price Target on Kiniksa Pharmaceuticals International to $44 From $38, Keeps Outperform Rating

MT Newswires Live
·
Oct 13, 2025